Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Study challenges concerns linking ADHD medication to self-harm risk (opens in a new tab)

news-medical.net · 2026-10-22

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Four of five claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 4 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe highest self-harm risk occurred during the 90 days immediately before starting treatment in all five healthcare systems, with lower but still elevated risks after treatment began.View evidenceHide evidence

As statedhighest in the 90 days immediately before starting treatment

Why this verdict

The pooled abstract-level results support the overall pattern of highest risk in the 90 days before initiation and lower but still elevated risks after treatment began. However, the claim that this exact highest-risk pattern occurred in all five healthcare systems is not fully verifiable from the abstract-level profile, which says results were consistent but does not provide site-specific IRRs or heterogeneity details.

1

Study evidence

Elevated self-harm rate in the 90 days before ADHD medication initiation compared with non-exposed periods.pooled adjusted IRR 2.58 (95% CI 2.12 to 3.13)

“We conducted a multinational self-controlled case series study using a common data modelling approach”
2

Study evidence

Cross-database SCCS estimates were reported as consistent across the five included health-system databases; pooled adjusted IRRs indicate highest risk in the 90 days before medication initiation, lower risk in the first 90 days of treatment, and lowest in the subsequent treatment period.Pooled adjusted IRRs for incident self-harm: 90 days pre-initiation 2.58 (95% CI 2.12–3.13); first 90 days on medication 1.78 (95% CI 1.23–2.57); subsequent treatment period 1.27 (95% CI 1.01–1.60).

“Results were consistent across included databases.”
Claim 2 of 5SupportedA new study led by Aston University found that self-harm risk among people with ADHD was highest before they started ADHD medication, rather than after treatment began.View evidenceHide evidence

As statedhighest before treatment begins

Why this verdict

The abstract-level profile supports the headline pattern: pooled adjusted IRR for incident self-harm was highest in the 90 days before ADHD medication initiation and lower during the first 90 days and subsequent treatment periods. The claim is framed as a risk-pattern finding rather than as proof of medication causation.

1

Study evidence

Elevated self-harm rate in the 90 days before ADHD medication initiation compared with non-exposed periods.pooled adjusted IRR 2.58 (95% CI 2.12 to 3.13)

“We conducted a multinational self-controlled case series study using a common data modelling approach”
Claim 3 of 5SupportedThe researchers analyzed data from more than 460,000 people across healthcare systems in Hong Kong, New Zealand, South Korea, Taiwan and the UK, comparing the 90 days before treatment, the first 90 days of treatment, and later treatment periods against non-exposure periods.View evidenceHide evidence

As statedmore than 460,000 people

Why this verdict

The profile reports 461,024 individuals with at least one ADHD medication prescription, databases from Hong Kong, New Zealand, South Korea, Taiwan and the UK, and comparison of the 90-day pre-initiation, first 90 days on treatment, and subsequent treatment periods against non-exposure periods using SCCS methods.

1

Study evidence

Elevated self-harm rate in the 90 days before ADHD medication initiation compared with non-exposed periods.pooled adjusted IRR 2.58 (95% CI 2.12 to 3.13)

“We conducted a multinational self-controlled case series study using a common data modelling approach”
2

Study evidence

Cross-database SCCS estimates were reported as consistent across the five included health-system databases; pooled adjusted IRRs indicate highest risk in the 90 days before medication initiation, lower risk in the first 90 days of treatment, and lowest in the subsequent treatment period.Pooled adjusted IRRs for incident self-harm: 90 days pre-initiation 2.58 (95% CI 2.12–3.13); first 90 days on medication 1.78 (95% CI 1.23–2.57); subsequent treatment period 1.27 (95% CI 1.01–1.60).

“Results were consistent across included databases.”
Claim 4 of 5SupportedThe researchers say the consistent findings do not support ADHD medications as the main driver of self-harm.View evidenceHide evidence

Why this verdict

The paper profile states that the authors interpret the highest pre-initiation risk pattern as not supporting ADHD medications as the main or primary driver of self-harm. The story attributes this conclusion to the researchers and uses cautious wording rather than asserting definitive causality.

1

Study evidence

Elevated self-harm rate in the 90 days before ADHD medication initiation compared with non-exposed periods.pooled adjusted IRR 2.58 (95% CI 2.12 to 3.13)

“We conducted a multinational self-controlled case series study using a common data modelling approach”
2

Study evidence

Cross-database SCCS estimates were reported as consistent across the five included health-system databases; pooled adjusted IRRs indicate highest risk in the 90 days before medication initiation, lower risk in the first 90 days of treatment, and lowest in the subsequent treatment period.Pooled adjusted IRRs for incident self-harm: 90 days pre-initiation 2.58 (95% CI 2.12–3.13); first 90 days on medication 1.78 (95% CI 1.23–2.57); subsequent treatment period 1.27 (95% CI 1.01–1.60).

“Results were consistent across included databases.”
Claim 5 of 5SupportedThe study suggests that closer monitoring and earlier intervention may be needed for people with ADHD, especially those whose symptoms are worsening before treatment starts.View evidenceHide evidence

Why this verdict

The abstract-level discussion supports the general implication that clinical monitoring and counselling are needed before and during treatment, especially given the elevated pre-initiation risk. The more specific phrase about people whose symptoms are worsening before treatment is best read as an interpretive gloss, but the claim is hedged and broadly aligned with the reported clinical implication.

1

Study evidence

Elevated self-harm rate in the 90 days before ADHD medication initiation compared with non-exposed periods.pooled adjusted IRR 2.58 (95% CI 2.12 to 3.13)

“We conducted a multinational self-controlled case series study using a common data modelling approach”
Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

4 things the story did carry across
  • Multinational self-controlled case series design using population-based healthcare databases and within-individual comparisons of defined medication-related risk windows against non-exposure periods.
  • Main quantitative pattern: pooled adjusted IRRs were highest before initiation, lower in the first 90 days on treatment, and lowest in the subsequent treatment period.
  • Authors’ interpretation: the observed pattern does not support ADHD medication as the primary driver of self-harm.
  • Clinical implication: monitoring and counselling are needed before and during ADHD medication treatment because risk was elevated before initiation as well as after treatment began.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate the association between ADHD medication exposure periods and incident self-harm risk using a multinational self-controlled case series (SCCS) analysis across multiple population-based healthcare databases, with site-specific estimates pooled via random-effects meta-analysis.self-controlled case series (SCCS)Expand

In plain English

Multinational self-controlled case series (SCCS) using population-based healthcare databases from Hong Kong, New Zealand, South Korea, Taiwan and the UK (2001–2020) evaluated within-individual rates of incident self-harm in relation to ADHD medication exposure. Conditional Poisson regression compared three predefined risk windows (90 days before medication initiation, first 90 days on medication, and subsequent treatment period) with non-exposed periods; site-specific adjusted incidence rate ratios (IRRs) were pooled using a random-effects model. Among 461,024 individuals with at least one ADHD medication prescription, 6,847 had an incident self-harm event. Pooled adjusted IRRs (95% CIs) were: 2.58 (2.12–3.13) for the 90 days before initiation, 1.78 (1.23–2.57) for the first 90 days on treatment, and 1.27 (1.01–1.60) for the subsequent treatment period. The highest risk occurred in the unexposed period immediately prior to treatment initiation; findings were reported as consistent across included databases, and the authors conclude the results do not support ADHD medications as the primary driver of self-harm but highlight the need for clinical monitoring before and during treatment.

Key findings

  • Elevated self-harm rate in the 90 days before ADHD medication initiation compared with non-exposed periods.pooled adjusted IRR 2.58 (95% CI 2.12 to 3.13)
  • Elevated self-harm rate in the first 90 days of ADHD medication use compared with non-exposed periods.pooled adjusted IRR 1.78 (95% CI 1.23 to 2.57)
“We conducted a multinational self-controlled case series study using a common data modelling approach”
2secondary dataAssess cross-database consistency/heterogeneity of the SCCS effect estimates across Hong Kong, New Zealand, South Korea, Taiwan and the United Kingdom under a common data model approach.Multinational SCCS with site-level estimation and random-effects poolingExpand

In plain English

The multinational self-controlled case series (SCCS) analysis applied a common data model across population databases in Hong Kong, New Zealand, South Korea, Taiwan and the United Kingdom and pooled site-level SCCS estimates using a random-effects model. The authors report that results were consistent across included databases; pooled adjusted incidence rate ratios (IRRs) for incident self-harm were 2.58 (95% CI 2.12–3.13) for the 90 days before medication initiation, 1.78 (95% CI 1.23–2.57) for the first 90 days of medication use, and 1.27 (95% CI 1.01–1.60) for the subsequent treatment period.

Key findings

  • Cross-database SCCS estimates were reported as consistent across the five included health-system databases; pooled adjusted IRRs indicate highest risk in the 90 days before medication initiation, lower risk in the first 90 days of treatment, and lowest in the subsequent treatment period.Pooled adjusted IRRs for incident self-harm: 90 days pre-initiation 2.58 (95% CI 2.12–3.13); first 90 days on medication 1.78 (95% CI 1.23–2.57); subsequent treatment period 1.27 (95% CI 1.01–1.60).
“Results were consistent across included databases.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Review for "Use of Antidepressants Decreased After Initiation of ADHD Treatment in Adults-A Finnish Nationwide Register Study Describing Use of ADHD and Non-ADHD Medication in People With and Without ADHD"

2025 · Crossref

Source (opens in a new tab)
Candidate

Epidemiology of Children and Young People Presenting to Australian Emergency Departments for the Management of Acute Severe Behavioural Disturbance: Secondary Analysis of a Randomised Controlled Trial.

Journal of Paediatrics and Child Health · 2026 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)

And 9 more candidates considered.